Toxicity evaluation by high-content analysis of 3D cultured primary human hepatocytes

DOI
  • ITO Toshimasa
    Pharmaceutical Sciences Division, Business Management Unit, SEKISUI MEDICAL CO., LTD.
  • FUJIMOTO Kazuhiro
    Pharmaceutical Sciences Division, Business Management Unit, SEKISUI MEDICAL CO., LTD.
  • FUJINO Ryo
    Pharmaceutical Sciences Division, Business Management Unit, SEKISUI MEDICAL CO., LTD.
  • KOBAYASHI Masato
    Pharmaceutical Sciences Division, Business Management Unit, SEKISUI MEDICAL CO., LTD.
  • FUJISHIMA Miki
    Pharmaceutical Sciences Division, Business Management Unit, SEKISUI MEDICAL CO., LTD.
  • NEGAMA Tsutomu
    Pharmaceutical Sciences Division, Business Management Unit, SEKISUI MEDICAL CO., LTD.

Bibliographic Information

Other Title
  • 3次元培養ヒト初代培養肝細胞のハイコンテントアナリシスによる毒性評価

Description

<p>DILI is one of the major reasons for drug discontinuation and withdrawal from the market, therefore highly predictive toxicity model is desired.　The development of liver toxicity is mediated by a variety of mechanisms, making it difficult to predict from a single biomarker. In these circumstances, we attempted to improve in vitro model for DILI detection by conducting HCA using 3D culture of human primary liver cells as a study to construct a liver toxicity model. Cells were exposed to multiple drugs causing DILI and were comprehensively evaluated using various toxicity biomarkers.</p>

Journal

Details 詳細情報について

  • CRID
    1390848647545108608
  • NII Article ID
    130007898420
  • DOI
    10.14869/toxpt.47.1.0_p-234
  • Text Lang
    ja
  • Data Source
    • JaLC
    • CiNii Articles
  • Abstract License Flag
    Disallowed

Report a problem

Back to top